Acorda Therapeutics, Inc. (NASDAQ:ACOR) went up by 7.89% from its latest closing price compared to the recent 1-year high of $4.04. The company’s stock price has collected 19.80% of gains in the last five trading sessions.
Is It Worth Investing in Acorda Therapeutics, Inc. (NASDAQ :ACOR) Right Now?
Plus, the 36-month beta value for ACOR is at 1.45. Opinions of the stock are interesting as 1 analysts out of 5 who provided ratings for Acorda Therapeutics, Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 3 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $3.00, which is -$0.55 below the current price. ACOR currently public float of 47.18M and currently shorts hold a 23.31% ratio of that float. Today, the average trading volume of ACOR was 2.08M shares.
ACOR’s Market Performance
ACOR stocks went up by 19.80% for the week, with a monthly drop of -13.24% and a quarterly performance of -34.21%, while its annual performance rate touched -83.78%. The volatility ratio for the week stands at 11.69% while the volatility levels for the past 30 days are set at 8.66% for Acorda Therapeutics, Inc.. The simple moving average for the period of the last 20 days is 4.22% for ACOR stocks with a simple moving average of -52.70% for the last 200 days.
Analysts’ Opinion of ACOR
Many brokerage firms have already submitted their reports for ACOR stocks, with H.C. Wainwright repeating the rating for ACOR by listing it as a “Neutral.” The predicted price for ACOR in the upcoming period, according to H.C. Wainwright is $6 based on the research report published on August 14th of the previous year 2019.
Wedbush , on the other hand, stated in their research note that they expect to see ACOR reach a price target of $6. The rating they have provided for ACOR stocks is “Neutral” according to the report published on May 23rd, 2019.
Goldman gave a rating of “ Sell” to ACOR, setting the target price at $6 in the report published on December 11th of the previous year.
ACOR Trading at -14.20% from the 50-Day Moving Average
After a stumble in the market that brought ACOR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.39% of loss for the given period.
Volatility was left at 8.66%, however, over the last 30 days, the volatility rate increased by 11.69%, as shares sank -9.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.64% lower at present.
During the last 5 trading sessions, ACOR rose by +19.80%, which changed the moving average for the period of 200-days by -65.63% in comparison to the 20-day moving average, which settled at $0.5248. In addition, Acorda Therapeutics, Inc. saw -73.04% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at ACOR starting from Wasman Jane, who sold 2,227 shares at the price of $1.60 back on Dec 02. After this action, Wasman Jane now owns 117,420 shares of Acorda Therapeutics, Inc., valued at $3,553 using the latest closing price.
Sabella Lauren M, the Chief Commercial Officer of Acorda Therapeutics, Inc., sold 1,513 shares at $1.60 during a trade that took place back on Dec 02, which means that Sabella Lauren M is holding 12,624 shares at $2,421 based on the most recent closing price.
Stock Fundamentals for ACOR
Current profitability levels for the company are sitting at:
- -60.60 for the present operating margin
- +68.56 for the gross margin
The net margin for Acorda Therapeutics, Inc. stands at -141.87. The total capital return value is set at -14.84, while invested capital returns managed to touch -35.39. Equity return is now at value -74.60, with -28.10 for asset returns.
Based on Acorda Therapeutics, Inc. (ACOR), the company’s capital structure generated 88.16 points at debt to equity in total, while total debt to capital is 46.85. Total debt to assets is 30.45, with long-term debt to equity ratio resting at -5.33. Finally, the long-term debt to capital ratio is 81.99.
When we switch over and look at the enterprise to sales, we see a ratio of 1.21, with the company’s debt to enterprise value settled at 1.18. The receivables turnover for the company is 8.46 and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.33.